Biomedical Engineering Reference
In-Depth Information
18.6 CONCLUSIONS
inhibitors:pokeweed antiviral protein or ricin A chain. Cancer
Res. 44, 1398-1404.
10. Ramakrishnan S, Enghlid JJ, Bryant HL. Jr., Xu FJ. (1989)
Characterization of a translation inhibitory protein from Luffa
aegyptiaca. Biochem. Biophys. Res. Commun. 160, 509-516.
11. Bolognesi A, Polito L, Tazzari PL, Lemoli RM, Lubelli C,
Fogli M. (2000) In vitro anti-tumor activity of anti-CD80
and anti-CD86 immunotoxins containing type 1 ribosome-
inactivating proteins. Br. J. Haematol. 110, 351-361.
12. Casellas P, Dussossoy D, Falasca AI, Barbieri L, Guillemot
JC, Ferrara P. (1988) Trichokirin, a ribosome-inactivating
protein from the seeds of Trichosanthes kirilowii Maximo-
wicz. Purification, partial characterization and use for prepa-
ration of immunotoxins. Eur. J. Biochem. 176, 581-588.
13. Wang QC, Ying WB, Xie H, Zhang ZC, Yang ZH, Ling LQ.
(1991) Trichosanthin-monoclonal antibody conjugate specif-
ically cytotoxic to human hepatoma cells in vitro. Cancer
Res. 51, 3353-3355.
14. OvadiaM, Hager CC, OeltmannTN. (1990) An antimelanoma-
barley ribosome inactivating protein conjugate is cytotoxic to
melanoma cells in vitro. Anticancer Res. 10, 671-675.
15. Citores L, Ferreras JM, Munoz R, Benitez J, Jimenez P,
Girbes T. (2002) Targeting cancer cells with transferrin
conjugates containing the non-toxic type 2 ribosome-
inactivating proteins nigrin b or ebulin l. Cancer Lett. 184,
29-35.
16. Francisco JA, Gawlak SL, Siegall CB. (1997) Construction,
expression, and characterization of BD1-G28-5 sFv, a single-
chain anti-CD40 immunotoxin containing the ribosome-
inactivating protein bryodin 1. J. Biol. Chem. 272, 24165-
24169.
17. Porro G, Bolognesi A, Caretto P, Gromo G, Lento P,
Mistza G, et al. (1993) In vitro and in vivo properties of
an anti-CD5-momordin immunotoxin on normal and neo-
plastic T lymphocytes. Cancer Immunol. Immunother. 36,
346-350.
18. Bolognesi A, Tazzari PL, Tassi C, Gromo G, Gobbi M, Stirpe
F. (1992) A comparison of anti-lymphocyte immunotoxins
containing different ribosome-inactivating proteins and anti-
bodies. Clin. Exp. Immunol. 89, 341-346.
19. Xia HC, Li F, Li Z, Zhang ZC. (2003) Purification and
characterization of Moschatin, a novel type I ribosome-
inactivating protein from the mature seeds of pumpkin
(Cucurbita moschata), and preparation of its immunotoxin
against human melanoma cells. Cell Res. 13, 369-374.
20. Bolognesi A, Tazzari PL, Legname G, Olivieri F, Modena D,
Conte R. (1995) Anti-CD30 immunotoxins with native and
recombinant dianthin 30. Cancer Immunol. Immunother. 40,
109-114.
21. Di Massimo AM, Di Loreto M, Pacilli A, Raucci G, D'Alatri
L, Mele A. (1997) Immunoconjugates made of an anti-EGF
receptor monoclonal antibody and type 1 ribosome-inactivat-
ing proteins from Saponaria ocymoides or Vaccaria pyrami-
data. Br. J. Cancer 75, 822-828.
22. Dosio F, Brusa P, Crosasso P, Fruttero C, Cattel L, Bolognesi
A. (1996) Synthesis of different immunotoxins composed by
Cytotoxic therapy with classic immunotoxins is a potential
treatment option for chemo-resistant relapsed/refractory
cancers because classic immunotoxins can selectively kill
target malignant cells by a different mechanism than con-
ventional chemotherapy. However, their clinical uses are
limited by immunogenicity and unwanted toxicity such as
VLS. To overcome these problems, studies on (1) develop-
ment of a standard clinical protocol for premedication and
antagonists for VLS motif binding, (2) improvement of
classic immunotoxin potencies, and (3) a new strategy to
avoid immunogenicity such as the use of deimmunized toxin
are needed. The success of these studies would warrant
safety and efficacy of classic immunotoxins in clinic.
REFERENCES
1. Greenfield L, Johnson VG, and Youle RJ. (1987) Mutations in
diphtheria toxin separate binding from entry and amplify
immunotoxin selectivity. Science 238, 536-539.
2. Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Willingham
MC, Pastan I. (1985) Anti-transferrin receptor antibody
linked to Pseudomonas exotoxin as a model immunotoxin
in human ovarian carcinoma cell lines. Cancer Res. 45,
751-757.
3. Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, Uhr
JW. (1983) Immunotoxins: a new approach to cancer therapy.
Science 219, 644-650.
4. Godal A, Fodstad O, Pihl A. (1987) Studies on the mechanism
of action of abrin-9.2.27 immunotoxin in human melanoma
cell lines. Cancer Res. 47, 6243-6247.
5. Wiedlocha A, Sandvig K, Walzel H, Radzikowsky C, Olsnes
S. (1991) Internalization and action of an immunotoxin
containing mistletoe lectin A-chain. Cancer Res. 51,
916-920.
6. Munoz R, Arias Y, Ferreras JM, Rojo MA, Gayoso MJ,
Nocito M. (2007) Targeting a marker of the tumour neo-
vasculature using a novel anti-human CD105-immunotoxin
containing the non-toxic type 2 ribosome-inactivating protein
nigrin b. Cancer Lett. 256, 73-80.
7. Lambert JM, Senter PD, Yau-Young A, Blattler WA,
Goldmacher VS. (1985) Purified immunotoxins that are
reactive with human lymphoid cells. Monoclonal antibodies
conjugated to the ribosome-inactivating proteins gelonin and
the pokeweed antiviral proteins. J. Biol. Chem. 260,
12035-12041.
8. Siena S, Lappi DA, Bregni M, Formosa A, Villa S, Soria M.
(1988) Synthesis and characterization of an antihuman
T-lymphocyte saporin immunotoxin (OKT1-SAP) with in
vivo stability into nonhuman primates. Blood 72, 756-765.
9. Ramakrishnan S, Houston LL. (1984) Prevention of growth of
leukemia cells in mice by monoclonal antibodies directed
against Thy 1.1 antigen disulfide linked to two ribosomal
Search WWH ::
Custom Search